Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

A randomized phase II trial of Mirvetuximab soravtansine (IMGN853), in folate receptor alpha (FRα) high recurrent ovarian cancer eligible fo… Ended

2024-516959-40-00 This trial evaluates the efficacy and safety of Mirvetu 4 2021-08-17
A Phase 1/2 Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants Wit… Ended

2023-503624-83-00 Anaemia associated with myelofibrosis 9 2021-08-16
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic… Ended

2023-506752-24-00 Locally recurrent inoperable or metastatic HR+/HER2- br 5 2021-08-05
A Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel versus Bortezomib, Len… Ended

2023-505850-16-00 Multiple Myeloma 5 2021-08-05
Evaluation of two maintenance therapies (OSE2101 alone or in combination with pembrolizumab) versus best supportive care in patient with pla… Ended

2024-516096-32-00 Platinum sensitive recurrent ovarian cancer 4 2021-08-05
Study of Subcutaneous Pembrolizumab versus Intravenous Pembrolizumab, Given with Chemotherapy, to Treat Metastatic Squamous or Non Squamous … Ended

2023-508308-40-00 Metastatic (stage IV) squamous or nonsquamous non-small 5 2021-07-30
DALY 2-EU Ended

2023-506270-13-00 Relapsed/refractory diffuse large B cell lymphoma (R-R 4 2021-07-27
Study of AZD5305 as Monotherapy and with Anti-Cancer Agents in Patients with Advanced Solid Malignancies Ended

2022-502856-29-00 Advanced Solid Tumors 7 2021-07-27
NADINA Ended

2024-513519-28-00 Stage III melanoma 5 2021-07-23
A Phase I Study of Belantamab Mafodotin in Multiple Myeloma Participants with Normal and Impaired Renal Function Ended

2023-506063-34-00 Relapsed/Refractory Multiple Myeloma 3 2021-07-23
Induction chemotherapy for locally advanced rectal cancer. Ended

2023-509758-74-00 Locally advanced rectal cancer 4 2021-07-21
DASL-HiCaP: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801). A randomised phase 3 dou… Ended

2024-514565-18-00 Localised Very High-Risk Cancer of the Prostate 5 2021-07-20
RECHALLENGE WITH PEGYLATED LIPOSOMAL DOXORUBICIN ADDED TO TRABECTEDIN IN RECURRENT OVARIAN CANCER: A MULTICENTER, PROSPECTIVE TRIAL.(REPRAB … Ended

2024-518847-40-00 recurrent ovarian cancer 4 2021-07-16
A Phase 1 Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer Ended

2023-506585-31-00 Metastatic castration-resistant prostate cancer 1 2021-07-09
A clinical study to compare Toripalimab (JS001) combined with Lenvatinib versus placebo combined with Lenvatinib as the 1st-line therapy for… Ended

2024-514207-34-00 Advanced hepatocellular carcinoma (HCC) 5 2021-07-08
A study to investigate anti-tumor activity and safety of trastuzumab deruxtecan in patients with solid tumors carrying specific HER2 mutatio… Ended

2024-516158-22-00 Treatment of unresectable and/or metastatic solid tumor 4 2021-07-06
A Phase 3 Open Label, Randomized Study of LOXO 305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab … Ended

2023-507697-40-00 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 5 2021-07-05
AIEOP-BFM 2017 POLAND - Collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia - A randomized phas… Ended

2024-517253-27-00 Acute lymphoblastic leukemia 5 2021-07-01
A Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-6036 as a Single Agent and in Combination with other Anti-Cancer Therap… Ended

2023-506311-18-00 Advanced or metastatic solid tumors with KRAS G12C muta 1 2021-06-29
Prospective, non randomized, Phase II study on MK-3475 in recurrent, platinum-resistant, CPS ≥1 positive ovarian, Fallopian tube and primary… Ended

2024-516629-30-00 Recurrent, platinum-resistant, CPS >1 positive ovarian, 4 2021-06-24
A Multi Arm Study in Participants with MSI-High Metastatic Colorectal Cancer Ended

2022-502100-70-00 Participants with Microsatellite Instability-High (MSI- 10 2021-06-23
Efficacy and Safety Comparison of Niraparib to Placebo in Participants with HER2 Negative BRCAmut or Triple-Negative Breast Cancer with Mole… Ended

2023-504454-35-00 Neoplasms, Breast 5 2021-06-22
Phase 2 study of neoadjuvant immune checkpoint inhibitors in urothelial cancer (ABACUS-2) Ended

2024-510750-28-00 Tumours of the urothelial tract requiring surgery (T1 h 4 2021-06-18
A phase 2, open label study to evaluate safety and clinical activity of balstilimab in monotherapy in patients with advanced/metastatic non-… Ended

2024-517380-22-00 Advanced basal cell carcinoma not amenable to local the 4 2021-06-18